ClinicalTrials.gg
CompletedNCT06342310Updated May 14, 2026

RE104 Safety and Efficacy Study in Postpartum Depression

A Phase 2 interventional study of RE104 for Injection in Postpartum Depression, sponsored by Reunion Neuroscience Inc. Completed at 38 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Reunion Neuroscience Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.

Enrollment
101st of 198
84 · median 86
Started
2024
with 10 others
Phase 2
18 of 220
none open now
Registered
188th of 220
by date

Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 101st largest by enrollment of the 198 interventional ones that give a count, is one of 11 that started in 2024, is one of 18 in phase 2, and was the 188th registered.

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Depression, Postpartum with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.

03

Conditions studied

  • Postpartum Depression
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is ≤15 months postpartum at Screening.
  • Meet criteria for postpartum depression (PPD): experiencing a major depressive episode that began at any time starting at the beginning of the second trimester (≥14 weeks) of pregnancy through 4 weeks post delivery.
  • Has a Hamilton Depression Scale (HAM-D) total score meeting severity threshold at Screening and Baseline.
  • Is not using any psychotropic medications or psychotherapy for 30 days prior to Screening, OR are on an already stable/established regimen of SSRIs or psychotherapy for 30 days prior to Screening.
  • Has ceased breastfeeding at Screening.
  • Has a negative pregnancy test at Screening and Day 0 prior to study drug administration.

Exclusion criteria

Exclusion Criteria:

  • History or active postpartum psychosis per Investigator assessment.
  • History of treatment-resistant depression within the current postpartum depressive episode.
  • Has a significant risk of suicide.
  • Active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder.
  • Medically significant condition rendering unsuitability for the study .
  • Has received electroconvulsive therapy (ECT) or transcranial magnetic stimulation within 90 days prior to Screening.
  • Has used psychedelics such as psilocybin, ayahuasca, mescaline, or LSD (with the exception of cannabis) within 12 months prior to Screening.
  • Has used or will need to use prohibited medications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Active comparator
    1.5 mg RE104

    A single subcutaneous injection of 1.5 mg RE104 for Injection

    Drug: RE104 for Injection

  • Experimental
    30 mg RE104

    A single subcutaneous injection of 30 mg RE104 for Injection

    Drug: RE104 for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score

    Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.

    Time frame: Day 7

Secondary outcomes

  1. RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score

    Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.

    Time frame: Day 1, Day 14 and Day 28

  2. RE104 30 mg versus RE104 1.5 mg percentage of patients with MADRS response (≥ 50 percent reduction in score from baseline)

    Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.

    Time frame: Day 7

  3. RE104 30 mg versus RE104 1.5 mg percentage of patients with MADRS remission (score ≤ to 10)

    Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.

    Time frame: Day 7

  4. RE104 30 mg versus RE104 1.5 mg Clinical Global Impression-Improvement (CGI-I)

    The Clinical Global Impression - Improvement (CGI-I) Scale is a clinician-rated instrument that weighs the clinical impact of the identified symptom(s) on behavior and function and measures changes in psychopathology since the treatment was administered on a scale from 1 (very much improved) to 7 (very much worse).

    Time frame: Day 1, Day 7 and Day 28

  5. RE104 30 mg versus RE104 1.5 mg change from baseline in CGI-Severity (CGI-S)

    The Clinical Global Impression - Severity Scale is a clinician-rated instrument that grades severity of symptoms on a scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients).

    Time frame: Day 1, Day 7 and Day 28

  6. RE104 30 mg versus RE104 1.5 mg changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)

    The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety.

    Time frame: Day 7

  7. RE104 30 mg versus RE104 1.5 mg incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.

    A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug.

    Time frame: From dosing through study completion (post-dose follow-up is for 28 days)

07

Study locations

38 sites
  • Reunion Investigational Site
    Birmingham, Alabama 35209, United States
  • Reunion Investigational Site
    Tucson, Arizona 85724, United States
  • Reunion Investigational Site
    Santa Monica, California 90404, United States
  • Reunion Investigational Site
    Boulder, Colorado 80045, United States
  • Reunion Investigational Site
    Denver, Colorado 80209, United States
  • Reunion Investigational Site
    Lauderhill, Florida 33319, United States
  • Reunion Investigational Site
    Tampa, Florida 33613, United States
  • Reunion Investigational Site
    Atlanta, Georgia 30329, United States
  • Reunion Investigational Site
    Atlanta, Georgia 30331, United States
  • Reunion Investigational Site
    Decatur, Georgia 30030, United States
  • Reunion Investigational Site
    Marietta, Georgia 30060, United States
  • Reunion Investigational Site
    Savannah, Georgia 31405, United States
  • Reunion Investigational Site
    Honolulu, Hawaii 96817, United States
  • Reunion Investigational Site
    Kansas City, Kansas 66160, United States
  • Reunion Investigational Site
    Shreveport, Louisiana 71106, United States
  • Reunion Investigational Site
    Baltimore, Maryland 21205, United States
  • Reunion Investigational Site
    Rockville, Maryland 20850, United States
  • Reunion Investigational Site
    Springfield, Massachusetts 01103, United States
  • Reunion Investigational Site
    Novi, Michigan 48377, United States
  • Reunion Investigational Site
    Albuquerque, New Mexico 87131, United States
  • Reunion Investigational Site
    Buffalo, New York 14202, United States
  • Reunion Investigational Site
    New York, New York 10016, United States
  • Reunion Investigational Site
    New York, New York 10026, United States
  • Reunion Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • Reunion Investigational Site
    Monroe, North Carolina 28112, United States
  • Reunion Investigational Site
    Cleveland, Ohio 44113, United States
  • Reunion Investigational Site
    Columbus, Ohio 43210, United States
  • Reunion Investigational Site
    West Chester, Pennsylvania 19380, United States
  • Reunion Investigational Site
    Austin, Texas 78712, United States
  • Reunion Investigational Site
    Austin, Texas 78737, United States
  • Reunion Investigational Site
    Austin, Texas 78759, United States
  • Reunion Investigational Site
    Plano, Texas 75093, United States
  • Reunion Investigational Site
    San Antonio, Texas 78229, United States
  • Reunion Investigational Site
    Draper, Utah 84020, United States
  • Reunion Investigational Site
    Salt Lake City, Utah 84108, United States
  • Reunion Investigational Site
    Charlottesville, Virginia 22903, United States
  • Reunion Investigational Site
    Seattle, Washington 98105, United States
  • Reunion Investigational Site
    Madison, Wisconsin 53719, United States
08

References and documents

Individual participant data

Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in May 2025, 11 months.

Of 14 phase 2 interventional studies under Depression, Postpartum, half reached primary completion within 17 months of starting (the median); a quarter within 10 and three quarters within 30. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Apr 2, 2024
StartActual
Jun 14, 2024
Primary completionActual
May 22, 2025
CompletionActual
Jun 16, 2025
Results delay requested
May 4, 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342310
Lead sponsor
Reunion Neuroscience Inc
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Jun 14, 2024
Primary completion
May 22, 2025
Completion
Jun 16, 2025
Last update
May 14, 2026

Study contacts

Jasna Hocevar-Trnka, M.D.
study director · Reunion Neuroscience Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luvesilocin

Start the discussion